Newron Pharmaceuticals S.p.A.
Research Newron Pharmaceuticals S.p.A. (NWRN.SW) on Bullrun: market cap CHF 166.03M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNWRN.SW
- ExchangeSW
- CountryItaly
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCHF
- Market capCHF 166.03M
- Financial periodFY2025
- RevenueEUR 19.13M
- Revenue growth-62.8%
- Net income-EUR 13.24M
- Free cash flowEUR 32.30M
Valuation Snapshot
latest market cap is CHF 166.03M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 19.13M | -EUR 13.24M | EUR 32.30M | n/a | n/a | EUR 12.19M | EUR 38.16M | -EUR 11.14M |
| FY2024 | EUR 51.39M | EUR 15.84M | -EUR 17.63M | n/a | 0.77 | EUR 6.93M | EUR 50.47M | EUR 1.46M |
| FY2023 | EUR 9.06M | -EUR 16.22M | -EUR 10.15M | n/a | -0.91 | EUR 6.34M | EUR 48.42M | -EUR 29.91M |
| FY2022 | EUR 6.09M | -EUR 17.49M | -EUR 11.11M | n/a | -0.98 | EUR 13.42M | EUR 45.66M | -EUR 14.03M |
| FY2021 | n/a | n/a | n/a | n/a | -0.84 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-04 | CHF 166.03M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 CHF.
About Newron Pharmaceuticals S.p.A.
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Newron Pharmaceuticals S.p.A.'s market cap?
Newron Pharmaceuticals S.p.A.'s market capitalization is CHF 166.03M.
What does Newron Pharmaceuticals S.p.A. do?
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan.